WO1998021320A3 - VARIANTES D'ACTIVATEUR PLASMINOGENE DE TYPE TISSULAIRE (t-PA): COMPOSITIONS ET TECHNIQUES D'UTILISATION - Google Patents

VARIANTES D'ACTIVATEUR PLASMINOGENE DE TYPE TISSULAIRE (t-PA): COMPOSITIONS ET TECHNIQUES D'UTILISATION Download PDF

Info

Publication number
WO1998021320A3
WO1998021320A3 PCT/US1997/020226 US9720226W WO9821320A3 WO 1998021320 A3 WO1998021320 A3 WO 1998021320A3 US 9720226 W US9720226 W US 9720226W WO 9821320 A3 WO9821320 A3 WO 9821320A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
compositions
methods
plasminogen activator
tissue type
Prior art date
Application number
PCT/US1997/020226
Other languages
English (en)
Other versions
WO1998021320A2 (fr
WO1998021320A9 (fr
Inventor
Edwin L Madison
Original Assignee
Scripps Research Inst
Edwin L Madison
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Edwin L Madison filed Critical Scripps Research Inst
Priority to EP97952176A priority Critical patent/EP0950095A2/fr
Priority to US09/600,985 priority patent/US6706504B1/en
Priority to CA002271697A priority patent/CA2271697C/fr
Priority to JP52266198A priority patent/JP2001505765A/ja
Priority to AU55850/98A priority patent/AU735519B2/en
Publication of WO1998021320A2 publication Critical patent/WO1998021320A2/fr
Publication of WO1998021320A3 publication Critical patent/WO1998021320A3/fr
Publication of WO1998021320A9 publication Critical patent/WO1998021320A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des variantes du facteur plasminogène tissulaire qui font preuve d'une amélioration notable de la stimulation de la fibrine, d'une discrimination considérablement accrue entre cofacteurs de la fibrine, d'une résistance marquée à l'inhibition par PAI-1, et d'une zymogénicité sensiblement accrue, une combinaison de propriétés qui renforcent l'utilité thérapeutique de l'enzyme.
PCT/US1997/020226 1996-11-12 1997-11-12 VARIANTES D'ACTIVATEUR PLASMINOGENE DE TYPE TISSULAIRE (t-PA): COMPOSITIONS ET TECHNIQUES D'UTILISATION WO1998021320A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP97952176A EP0950095A2 (fr) 1996-11-12 1997-11-12 VARIANTES D'ACTIVATEUR PLASMINOGENE DE TYPE TISSULAIRE (t-PA): COMPOSITIONS ET TECHNIQUES D'UTILISATION
US09/600,985 US6706504B1 (en) 1996-11-12 1997-11-12 Tissue type plasminogen activator (t-PA) variants: compositions and methods of use
CA002271697A CA2271697C (fr) 1996-11-12 1997-11-12 Variantes d'activateur plasminogene de type tissulaire (t-pa): compositions et techniques d'utilisation
JP52266198A JP2001505765A (ja) 1996-11-12 1997-11-12 組織型プラスミノーゲンアクチベーター（ｔ―ＰＡ）の変異体：組成物およびその使用方法
AU55850/98A AU735519B2 (en) 1996-11-12 1997-11-12 Tissue type plasminogen activator (t-PA) variants: compositions and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3065596P 1996-11-12 1996-11-12
US60/030,655 1996-11-12

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09/600,985 A-371-Of-International US6706504B1 (en) 1996-11-12 1997-11-12 Tissue type plasminogen activator (t-PA) variants: compositions and methods of use
US09600985 A-371-Of-International 1997-11-12
US10/705,633 Division US6869778B2 (en) 1996-11-12 2003-11-10 Tissue type plasminogen activator (t-PA) variants: compositions and methods of use

Publications (3)

Publication Number Publication Date
WO1998021320A2 WO1998021320A2 (fr) 1998-05-22
WO1998021320A3 true WO1998021320A3 (fr) 1998-07-09
WO1998021320A9 WO1998021320A9 (fr) 1998-08-27

Family

ID=21855292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/020226 WO1998021320A2 (fr) 1996-11-12 1997-11-12 VARIANTES D'ACTIVATEUR PLASMINOGENE DE TYPE TISSULAIRE (t-PA): COMPOSITIONS ET TECHNIQUES D'UTILISATION

Country Status (6)

Country Link
EP (1) EP0950095A2 (fr)
JP (1) JP2001505765A (fr)
CN (1) CN1244894A (fr)
AU (1) AU735519B2 (fr)
CA (1) CA2271697C (fr)
WO (1) WO1998021320A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8864398A (en) * 1997-08-13 1999-03-08 Boehringer Mannheim Gmbh Plasminogen activator with enhanced zymogenic power and reduced fibrin linking
US10160813B2 (en) * 2013-01-22 2018-12-25 University Of Tennessee Research Foundation Tissue plasminogen activator antibodies and methods of use
CN114736948B (zh) * 2022-06-10 2022-11-08 深圳市帝迈生物技术有限公司 一种α2-抗纤溶酶活性测定试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199574A2 (fr) * 1985-04-22 1986-10-29 Genentech, Inc. Mutants d'activateur de plasminogène tissulaire humain, méthodes et intermédiaires pour ceux-ci et compositions utilisant ces mutants
WO1990002798A1 (fr) * 1988-09-02 1990-03-22 Genentech, Inc. Activateur de plasminogene tissulaire presentant des proprietes specifiques zymogenes ou specifiques a la fibrine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199574A2 (fr) * 1985-04-22 1986-10-29 Genentech, Inc. Mutants d'activateur de plasminogène tissulaire humain, méthodes et intermédiaires pour ceux-ci et compositions utilisant ces mutants
WO1990002798A1 (fr) * 1988-09-02 1990-03-22 Genentech, Inc. Activateur de plasminogene tissulaire presentant des proprietes specifiques zymogenes ou specifiques a la fibrine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PETERSEN L C ET AL: "QUENCHING OF THE AMIDOLYTIC ACTIVITY OF ONE-CHAIN TISSUE-TYPE PLASMINOGEN ACTIVATOR BY MUTATION OF LYSINE-416", BIOCHEMISTRY, vol. 29, no. 14, 1990, WASHINGTON US, pages 3451 - 3457, XP002053064 *
TACHIAS K ET AL: "Variants of tissue-type plasminogen activator which display substantially enhanced stimulation by fibrin", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 31, 4 August 1995 (1995-08-04), BALTIMORE US, pages 18319 - 18322, XP002063362 *

Also Published As

Publication number Publication date
CN1244894A (zh) 2000-02-16
AU5585098A (en) 1998-06-03
WO1998021320A2 (fr) 1998-05-22
EP0950095A2 (fr) 1999-10-20
CA2271697C (fr) 2007-10-23
AU735519B2 (en) 2001-07-12
CA2271697A1 (fr) 1998-05-22
JP2001505765A (ja) 2001-05-08

Similar Documents

Publication Publication Date Title
AU3645697A (en) Amidinoindoles, amidinoazoles, and analogs thereof as inhibitors of factor xa and of thrombin
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
CA2288948A1 (fr) Arginine deiminase modifiee
EP0278696A3 (fr) Inhibiteur du type arg-serpin d'activateur de plasminogène humaine désigné PAI-2
AU677540B2 (en) High-strength line-pipe steel having low yield ratio and excellent low-temperature toughness
CA2295693A1 (fr) .alpha.-amylase mutante comportant une liaison disulfure
AU1926001A (en) Novel human protein kinases and protein kinase-like enzymes
AU1515295A (en) Inhibitors of urokinase plasminogen activator
AU2002310008A1 (en) Composition with enhance cetylpyridinium chloride activity and method of using the same
UA70919C2 (uk) Композиція для лікування та запобігання артеріальному тромбозу з використанням інгібітора фактора ха окремо або в комбінації з препаратом, що унеможливлює агрегацію тромбоцитів
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
EP0833912A4 (fr) Nouvelle cytokine de type facteur de croissance transformant tgf-beta
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
AU7690498A (en) Cleavage of fibrin(ogen) and cross-linked fibrin by fibrinolytic matrix metalloproteinases
AU3951995A (en) Urokinase plasminogen activator fragments
AU7431796A (en) Brain-associated inhibitor of tissue-type plasminogen activator
WO1998021320A3 (fr) VARIANTES D'ACTIVATEUR PLASMINOGENE DE TYPE TISSULAIRE (t-PA): COMPOSITIONS ET TECHNIQUES D'UTILISATION
WO1999057133A3 (fr) NOUVEAUX INHIBITEURS D'ACTIVATION NF-λB
AU2001234544A1 (en) Novel human protein kinases and protein kinase-like enzymes
AU2001247471A1 (en) Compositions and methods of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxyflavones
AU3729300A (en) Brain-associated inhibitor of tissue-type plasminogen activator
AU5134990A (en) Mutants of urinary plasminogen activator, their production and use
WO2003053999A3 (fr) Inhibiteurs selectifs d'urokinase
BG104914A (en) Paroxetine maleate
AU5619700A (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97181346.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

CFP Corrected version of a pamphlet front page

Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2271697

Country of ref document: CA

Ref document number: 1998 522661

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 55850/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1997952176

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997952176

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09600985

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 55850/98

Country of ref document: AU